DK0643585T3 - Anvendelsen af lipoprotein-associeret koagulationsinhibitor (LACI) til fremstilling af et lægemiddel til behandlingen af ak - Google Patents

Anvendelsen af lipoprotein-associeret koagulationsinhibitor (LACI) til fremstilling af et lægemiddel til behandlingen af ak

Info

Publication number
DK0643585T3
DK0643585T3 DK93910775T DK93910775T DK0643585T3 DK 0643585 T3 DK0643585 T3 DK 0643585T3 DK 93910775 T DK93910775 T DK 93910775T DK 93910775 T DK93910775 T DK 93910775T DK 0643585 T3 DK0643585 T3 DK 0643585T3
Authority
DK
Denmark
Prior art keywords
laci
inhibitor
treatment
lipoprotein
drug
Prior art date
Application number
DK93910775T
Other languages
English (en)
Inventor
Abla A Creasey
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of DK0643585T3 publication Critical patent/DK0643585T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DK93910775T 1992-06-01 1993-04-23 Anvendelsen af lipoprotein-associeret koagulationsinhibitor (LACI) til fremstilling af et lægemiddel til behandlingen af ak DK0643585T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89194792A 1992-06-01 1992-06-01
US450593A 1993-01-13 1993-01-13
PCT/US1993/003860 WO1993024143A1 (en) 1992-06-01 1993-04-23 A method for using lipoprotein associated coagulation inhibitor to treat sepsis

Publications (1)

Publication Number Publication Date
DK0643585T3 true DK0643585T3 (da) 2000-05-08

Family

ID=26673093

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93910775T DK0643585T3 (da) 1992-06-01 1993-04-23 Anvendelsen af lipoprotein-associeret koagulationsinhibitor (LACI) til fremstilling af et lægemiddel til behandlingen af ak

Country Status (10)

Country Link
EP (1) EP0643585B1 (da)
JP (3) JP3957740B2 (da)
AT (1) ATE187648T1 (da)
CA (1) CA2136953C (da)
DE (1) DE69327314T2 (da)
DK (1) DK0643585T3 (da)
ES (1) ES2139658T3 (da)
GR (1) GR3032779T3 (da)
PT (1) PT643585E (da)
WO (1) WO1993024143A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824644A (en) * 1994-07-07 1998-10-20 G. D. Searle & Co. Method of attenuating arterial stenosis
US5648331A (en) * 1994-08-26 1997-07-15 G.D. Searle & Co. Method of inhibiting tissue ischemia and reperfusion injury
US5914316A (en) * 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
WO1996040224A1 (en) * 1995-06-07 1996-12-19 Chiron Corporation Regulation of cytokine synthesis and release
US5772629A (en) * 1995-10-23 1998-06-30 Localmed, Inc. Localized intravascular delivery of TFPI for inhibition of restenosis in recanalized blood vessels
US5981471A (en) * 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
EP1141313A2 (en) 1998-12-31 2001-10-10 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
JP2004537497A (ja) * 2000-11-08 2004-12-16 ザ ジェネラル ホスピタル コーポレーション 疼痛を阻害するための方法
US6939716B2 (en) 2001-09-19 2005-09-06 Washington University Method for detecting conditions indicative of sepsis
MXPA04003547A (es) 2001-10-15 2004-07-22 Chiron Corp Tratamiento de sepsis mediante administracion de dosis bajas de inhibidor de via factor de tejido.
WO2005019265A1 (en) 2003-08-13 2005-03-03 Chiron Corporation Improved method of purifying tfpi and tfpi analogs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK408089D0 (da) * 1989-08-18 1989-08-18 Novo Nordisk As Proteiner

Also Published As

Publication number Publication date
EP0643585A1 (en) 1995-03-22
ES2139658T3 (es) 2000-02-16
CA2136953A1 (en) 1993-12-09
JPH07507300A (ja) 1995-08-10
DE69327314T2 (de) 2000-04-13
DE69327314D1 (de) 2000-01-20
JP2007137901A (ja) 2007-06-07
ATE187648T1 (de) 2000-01-15
EP0643585B1 (en) 1999-12-15
GR3032779T3 (en) 2000-06-30
PT643585E (pt) 2000-05-31
WO1993024143A1 (en) 1993-12-09
JP3957740B2 (ja) 2007-08-15
CA2136953C (en) 2006-10-31
JP2004210801A (ja) 2004-07-29

Similar Documents

Publication Publication Date Title
DE69738948D1 (de) Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten
DE68919358D1 (de) Zusammensetzung zur behandlung der schizophrenie.
AR002254A1 (es) Formulacion antitrombotica y procedimiento para su manufactura
DE69327263D1 (de) Verwendung des Gewebefaktor-Inhibitors zur Herstellung eines Arzneimittels gegen Mikrogefässthrombose
PT94869A (pt) Processo de preparacao de uma composicao terapeutica a base de moleculas de anticorpos anti-cd14
DK0643585T3 (da) Anvendelsen af lipoprotein-associeret koagulationsinhibitor (LACI) til fremstilling af et lægemiddel til behandlingen af ak
AU5051693A (en) Method and composition for treating inflammatory bowel disorders
MC2078A1 (fr) Emploi d'alezastine comme matiere active contre le psoriasis et des maladies inflammatoires
DE69328838T2 (de) Antipyretische und analgetische verfahren und zusammensetzungen, die optisch reines r-etodolac enthalten
IT1293305B1 (it) Sali di acidi difosfonici e loro impiego farmacologico nel trattamento dell'osteoporosi
ES2123004T3 (es) Uso de factor de crecimiento derivado de plaquetas en la preparacion de un medicamento para el tratamiento de ulceras gastrointestinales.
DE69307702D1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
NO984196L (no) FremgangsmÕte for behandling av stoffmisbruk
DE69800906D1 (de) Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
NO984198L (no) FremgangsmÕte for behandling av aggresjon
NO961180L (no) Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom
DK563886A (da) Terapeutisk komposition
RU94025290A (ru) Способ лечения воспалительных осложнений при чрескостном остеосинтезе длинных трубчатых костей в условиях гнойной инфекции
MY110416A (en) Composition for the treatment of schizophrenia.
ITMI910114V0 (it) Struttura di calza ortopedica in particolare per la cura e la prevenzione del valgismo dell'alluce